Allianz Asset Management
CTMX icon

Allianz Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Allianz Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-38,660
Closed -$321K – 2513
2019
Q4 		$321K Sell
38,660
-103,991
-73% -$702K ﹤0.01% 2553
2019
Q3 		$1.06M Sell
142,651
-38,002
-21% -$375K ﹤0.01% 2102
2019
Q2 		$2.03M Sell
180,653
-152,747
-46% -$1.6M ﹤0.01% 1877
2019
Q1 		$3.58M Buy
333,400
+32,274
+11% +$477K ﹤0.01% 1607
2018
Q4 		$4.54M Sell
301,126
-145,097
-33% -$2.15M 0.01% 1449
2018
Q3 		$8.26M Buy
446,223
+92,693
+26% +$2.11M 0.01% 1356
2018
Q2 		$8.08M Buy
353,530
+294,791
+502% +$7.53M 0.01% 1336
2018
Q1 		$1.67M Buy
58,739
+4,036
+7% +$115K ﹤0.01% 2003
2017
Q4 		$1.16M Sell
54,703
-85
-0.2% -$1.76K ﹤0.01% 2192
2017
Q3 		$995K Buy
+54,788
New +$855K ﹤0.01% 2256

Other funds holding CTMX

Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Allianz Asset Management's CTMX Position: Q1 2020 in Review

Allianz Asset Management sold out of CytomX Therapeutics (CTMX) in Q1 2020, closing a stake of 38,660 shares — an estimated $321K sold.

Allianz Asset Management first reported a position in CTMX in Q3 2017 and held it in 10 quarters. The position peaked at $8.26M in Q3 2018. 117 funds tracked by Wall St. Rank hold CTMX as of Q1 2020.

  • Allianz Asset Management reported no remaining CytomX Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Allianz Asset Management sold 38,660 CytomX Therapeutics shares in Q1 2020, an estimated $321K.
  • Allianz Asset Management first reported a position in CytomX Therapeutics in Q3 2017 and held it in 10 quarters.
  • Allianz Asset Management's CytomX Therapeutics position peaked at $8.26M in Q3 2018.
  • 117 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2020.

Based on Allianz Asset Management's 13F filing for Q1 2020, filed 14 May 2020.